rheumatoid arthritis
Conditions
Interventions
In patients with clinical remission by adalimumab (DAS28-CRP <
2.6) maintained over 24 weeks, to stop the Adalimumab.
Sponsors
Osaka City University Medical School
Metabolism, Endocrinology, and Molecular Medicine. Osaka City University Graduate School of Medicine. The center for rheumatic diseases. Nara Medical University. Rheumatology. Kitano Hospital.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: RA patients fulling the American Rheumatology Association criteria 1987 and ACR/EULAR classification cliteria 2010. The patients using adalimumab who have stable remission, as a 28-joint disease activity score CRP (DAS28-CRP) <2.6 for at least 24 weeks.
Exclusion criteria
Exclusion criteria: Patients with other diseases that can affect the infllamation state. Patients using corticosteroids exceeding 5mg/day. Patients who was deemed inappropriate by test doctor to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Consider the possible state by results of ultrasound in the presence or absence of recurrence (DAS28-CRP <3.2) at week 24 after discontinuation of Adalimumab. | — |
Secondary
| Measure | Time frame |
|---|---|
| Consider the possible state by results of ultrasound in the presence or absence of recurrence (DAS28-CRP <3.2) at week 52 after discontinuation of Adalimumab. the change of X-ray from baseline in the van der Heijde-Sharp score at week 24 and 52. the change of ultrasound results from baseline at week 24and 52 | — |
Countries
Japan
Contacts
Public ContactTadashi Okano
Osaka City University Medical School Orthopedic Surgery
Outcome results
None listed